Sodium Reduction, Metabolomic Profiling, and Cardiovascular Disease Risk in Untreated Black Hypertensives: A Randomized, Double-Blind, Placebo-Controlled Trial

Dietary sodium restriction has multiple beneficial effects on cardiovascular health. The underlying mechanisms are not fully understood, and the roles of metabolomics have been rarely studied. We aimed to test the hypothesis that the reduction in dietary sodium intake would induce changes in metabol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2019-07, Vol.74 (1), p.194-200
Hauptverfasser: Chen, Li, He, Feng J, Dong, Yanbin, Huang, Ying, Harshfield, Gregory A, Zhu, Haidong
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 200
container_issue 1
container_start_page 194
container_title Hypertension (Dallas, Tex. 1979)
container_volume 74
creator Chen, Li
He, Feng J
Dong, Yanbin
Huang, Ying
Harshfield, Gregory A
Zhu, Haidong
description Dietary sodium restriction has multiple beneficial effects on cardiovascular health. The underlying mechanisms are not fully understood, and the roles of metabolomics have been rarely studied. We aimed to test the hypothesis that the reduction in dietary sodium intake would induce changes in metabolomic profiling among black hypertensives, and the changes would be associated with reduced blood pressure (BP) and improved skin capillary density. A total of 64 untreated black hypertensives were included from a randomized, double-blind, placebo-controlled cross-over trial of sodium reduction. The participants were given either 9 slow sodium tablets (10 mmol sodium per tablet) or placebo tablets daily for 6 weeks, they then crossed over to receive the other tablets for another 6 weeks, while on reduced sodium diet aiming at achieving daily sodium intake around 2.0 g. Untargeted metabolomic profiling was performed in paired serum samples, which were collected at the end of each period, so were BP and capillary density. Mixed-effects models were used. There were 34 metabolites identified with raw P’s
doi_str_mv 10.1161/HYPERTENSIONAHA.119.12880
format Article
fullrecord <record><control><sourceid>wolterskluwer_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1161_HYPERTENSIONAHA_119_12880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10.1161/HYPERTENSIONAHA.119.12880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2590-69f031715323898da7acc0ceb620feeb6b9c8431b4384a8cefefcbdf527ee4403</originalsourceid><addsrcrecordid>eNqNkMtOwzAURC0EEqXwD2bfFDtx2hiJRV9QpFKqPiRYRY5zQ03duLKTIvgZfhVDWbFiNZqRzlkMQpeUtCnt0Kvx82w0X46mi_vHaW_c8yNv0zBJyBFq0DhkAYs70TFqEMpZwCl9OkVnzr0SQhlj3Qb6XJhc1Vs8h7yWlTJlCz9AJTKjzVZJPLOmUFqVLy0syhwPhM2V2Qsnay0sHioHwgGeK7fBqsSrsrIgKshxXwu5weP3HdgKSqf24K5xD8-9xHs_IG_hoakzDUHf232beQAyEwyMdxitvWNpldDn6KQQ2sHFbzbR6na0HIyDyePd_aA3CWQYcxJ0eEEi2qVxFEYJT3LRFVISb-yEpAAfGZcJi2jGooSJREIBhczyIg67AIyRqIn4wSutcc5Cke6s2gr7nlKSfj-d_nnajzz9edqzNwf2zegKrNvo-g1sugahq_U_-C_J5osC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Sodium Reduction, Metabolomic Profiling, and Cardiovascular Disease Risk in Untreated Black Hypertensives: A Randomized, Double-Blind, Placebo-Controlled Trial</title><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Chen, Li ; He, Feng J ; Dong, Yanbin ; Huang, Ying ; Harshfield, Gregory A ; Zhu, Haidong</creator><creatorcontrib>Chen, Li ; He, Feng J ; Dong, Yanbin ; Huang, Ying ; Harshfield, Gregory A ; Zhu, Haidong</creatorcontrib><description>Dietary sodium restriction has multiple beneficial effects on cardiovascular health. The underlying mechanisms are not fully understood, and the roles of metabolomics have been rarely studied. We aimed to test the hypothesis that the reduction in dietary sodium intake would induce changes in metabolomic profiling among black hypertensives, and the changes would be associated with reduced blood pressure (BP) and improved skin capillary density. A total of 64 untreated black hypertensives were included from a randomized, double-blind, placebo-controlled cross-over trial of sodium reduction. The participants were given either 9 slow sodium tablets (10 mmol sodium per tablet) or placebo tablets daily for 6 weeks, they then crossed over to receive the other tablets for another 6 weeks, while on reduced sodium diet aiming at achieving daily sodium intake around 2.0 g. Untargeted metabolomic profiling was performed in paired serum samples, which were collected at the end of each period, so were BP and capillary density. Mixed-effects models were used. There were 34 metabolites identified with raw P’s&lt;0.05. Among those, 2 metabolites including β-hydroxyisovalerate and methionine sulfone were significantly increased with sodium reduction (false discovery rate =0.006 and 0.099, respectively). Increased β-hydroxyisovalerate was associated with reduced office systolic BP and ambulatory daytime systolic BP, whereas increased methionine sulfone was associated with reduced 24-hour diastolic BP, ambulatory nighttime diastolic BP, and increased skin capillary density. Our results suggest that dietary sodium reduction increases the circulating levels of β-hydroxyisovalerate and methionine sulfone. Further studies are warranted. CLINICAL TRIAL REGISTRATION—URLhttp://www.clinicaltrials.gov. Unique identifierNCT00152074.</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/HYPERTENSIONAHA.119.12880</identifier><language>eng</language><publisher>American Heart Association, Inc</publisher><ispartof>Hypertension (Dallas, Tex. 1979), 2019-07, Vol.74 (1), p.194-200</ispartof><rights>2019 American Heart Association, Inc</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2590-69f031715323898da7acc0ceb620feeb6b9c8431b4384a8cefefcbdf527ee4403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3687,27924,27925</link.rule.ids></links><search><creatorcontrib>Chen, Li</creatorcontrib><creatorcontrib>He, Feng J</creatorcontrib><creatorcontrib>Dong, Yanbin</creatorcontrib><creatorcontrib>Huang, Ying</creatorcontrib><creatorcontrib>Harshfield, Gregory A</creatorcontrib><creatorcontrib>Zhu, Haidong</creatorcontrib><title>Sodium Reduction, Metabolomic Profiling, and Cardiovascular Disease Risk in Untreated Black Hypertensives: A Randomized, Double-Blind, Placebo-Controlled Trial</title><title>Hypertension (Dallas, Tex. 1979)</title><description>Dietary sodium restriction has multiple beneficial effects on cardiovascular health. The underlying mechanisms are not fully understood, and the roles of metabolomics have been rarely studied. We aimed to test the hypothesis that the reduction in dietary sodium intake would induce changes in metabolomic profiling among black hypertensives, and the changes would be associated with reduced blood pressure (BP) and improved skin capillary density. A total of 64 untreated black hypertensives were included from a randomized, double-blind, placebo-controlled cross-over trial of sodium reduction. The participants were given either 9 slow sodium tablets (10 mmol sodium per tablet) or placebo tablets daily for 6 weeks, they then crossed over to receive the other tablets for another 6 weeks, while on reduced sodium diet aiming at achieving daily sodium intake around 2.0 g. Untargeted metabolomic profiling was performed in paired serum samples, which were collected at the end of each period, so were BP and capillary density. Mixed-effects models were used. There were 34 metabolites identified with raw P’s&lt;0.05. Among those, 2 metabolites including β-hydroxyisovalerate and methionine sulfone were significantly increased with sodium reduction (false discovery rate =0.006 and 0.099, respectively). Increased β-hydroxyisovalerate was associated with reduced office systolic BP and ambulatory daytime systolic BP, whereas increased methionine sulfone was associated with reduced 24-hour diastolic BP, ambulatory nighttime diastolic BP, and increased skin capillary density. Our results suggest that dietary sodium reduction increases the circulating levels of β-hydroxyisovalerate and methionine sulfone. Further studies are warranted. CLINICAL TRIAL REGISTRATION—URLhttp://www.clinicaltrials.gov. Unique identifierNCT00152074.</description><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkMtOwzAURC0EEqXwD2bfFDtx2hiJRV9QpFKqPiRYRY5zQ03duLKTIvgZfhVDWbFiNZqRzlkMQpeUtCnt0Kvx82w0X46mi_vHaW_c8yNv0zBJyBFq0DhkAYs70TFqEMpZwCl9OkVnzr0SQhlj3Qb6XJhc1Vs8h7yWlTJlCz9AJTKjzVZJPLOmUFqVLy0syhwPhM2V2Qsnay0sHioHwgGeK7fBqsSrsrIgKshxXwu5weP3HdgKSqf24K5xD8-9xHs_IG_hoakzDUHf232beQAyEwyMdxitvWNpldDn6KQQ2sHFbzbR6na0HIyDyePd_aA3CWQYcxJ0eEEi2qVxFEYJT3LRFVISb-yEpAAfGZcJi2jGooSJREIBhczyIg67AIyRqIn4wSutcc5Cke6s2gr7nlKSfj-d_nnajzz9edqzNwf2zegKrNvo-g1sugahq_U_-C_J5osC</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Chen, Li</creator><creator>He, Feng J</creator><creator>Dong, Yanbin</creator><creator>Huang, Ying</creator><creator>Harshfield, Gregory A</creator><creator>Zhu, Haidong</creator><general>American Heart Association, Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201907</creationdate><title>Sodium Reduction, Metabolomic Profiling, and Cardiovascular Disease Risk in Untreated Black Hypertensives: A Randomized, Double-Blind, Placebo-Controlled Trial</title><author>Chen, Li ; He, Feng J ; Dong, Yanbin ; Huang, Ying ; Harshfield, Gregory A ; Zhu, Haidong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2590-69f031715323898da7acc0ceb620feeb6b9c8431b4384a8cefefcbdf527ee4403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Li</creatorcontrib><creatorcontrib>He, Feng J</creatorcontrib><creatorcontrib>Dong, Yanbin</creatorcontrib><creatorcontrib>Huang, Ying</creatorcontrib><creatorcontrib>Harshfield, Gregory A</creatorcontrib><creatorcontrib>Zhu, Haidong</creatorcontrib><collection>CrossRef</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Li</au><au>He, Feng J</au><au>Dong, Yanbin</au><au>Huang, Ying</au><au>Harshfield, Gregory A</au><au>Zhu, Haidong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sodium Reduction, Metabolomic Profiling, and Cardiovascular Disease Risk in Untreated Black Hypertensives: A Randomized, Double-Blind, Placebo-Controlled Trial</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><date>2019-07</date><risdate>2019</risdate><volume>74</volume><issue>1</issue><spage>194</spage><epage>200</epage><pages>194-200</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><abstract>Dietary sodium restriction has multiple beneficial effects on cardiovascular health. The underlying mechanisms are not fully understood, and the roles of metabolomics have been rarely studied. We aimed to test the hypothesis that the reduction in dietary sodium intake would induce changes in metabolomic profiling among black hypertensives, and the changes would be associated with reduced blood pressure (BP) and improved skin capillary density. A total of 64 untreated black hypertensives were included from a randomized, double-blind, placebo-controlled cross-over trial of sodium reduction. The participants were given either 9 slow sodium tablets (10 mmol sodium per tablet) or placebo tablets daily for 6 weeks, they then crossed over to receive the other tablets for another 6 weeks, while on reduced sodium diet aiming at achieving daily sodium intake around 2.0 g. Untargeted metabolomic profiling was performed in paired serum samples, which were collected at the end of each period, so were BP and capillary density. Mixed-effects models were used. There were 34 metabolites identified with raw P’s&lt;0.05. Among those, 2 metabolites including β-hydroxyisovalerate and methionine sulfone were significantly increased with sodium reduction (false discovery rate =0.006 and 0.099, respectively). Increased β-hydroxyisovalerate was associated with reduced office systolic BP and ambulatory daytime systolic BP, whereas increased methionine sulfone was associated with reduced 24-hour diastolic BP, ambulatory nighttime diastolic BP, and increased skin capillary density. Our results suggest that dietary sodium reduction increases the circulating levels of β-hydroxyisovalerate and methionine sulfone. Further studies are warranted. CLINICAL TRIAL REGISTRATION—URLhttp://www.clinicaltrials.gov. Unique identifierNCT00152074.</abstract><pub>American Heart Association, Inc</pub><doi>10.1161/HYPERTENSIONAHA.119.12880</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0194-911X
ispartof Hypertension (Dallas, Tex. 1979), 2019-07, Vol.74 (1), p.194-200
issn 0194-911X
1524-4563
language eng
recordid cdi_crossref_primary_10_1161_HYPERTENSIONAHA_119_12880
source American Heart Association Journals; EZB-FREE-00999 freely available EZB journals
title Sodium Reduction, Metabolomic Profiling, and Cardiovascular Disease Risk in Untreated Black Hypertensives: A Randomized, Double-Blind, Placebo-Controlled Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T06%3A12%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sodium%20Reduction,%20Metabolomic%20Profiling,%20and%20Cardiovascular%20Disease%20Risk%20in%20Untreated%20Black%20Hypertensives:%20A%20Randomized,%20Double-Blind,%20Placebo-Controlled%20Trial&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Chen,%20Li&rft.date=2019-07&rft.volume=74&rft.issue=1&rft.spage=194&rft.epage=200&rft.pages=194-200&rft.issn=0194-911X&rft.eissn=1524-4563&rft_id=info:doi/10.1161/HYPERTENSIONAHA.119.12880&rft_dat=%3Cwolterskluwer_cross%3E10.1161/HYPERTENSIONAHA.119.12880%3C/wolterskluwer_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true